Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma (Q41768357)
Jump to navigation
Jump to search
scientific article published on 28 September 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma |
scientific article published on 28 September 2013 |
Statements
1 reference
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma (English)
1 reference
Neeraj Agarwal
Joaquim Bellmunt
Benjamin L Maughan
Angela Q Qu
Nicholas J Vogelzang
Ronan Fougeray
Peter Albers
Yu-Ning Wong
Yoo-Joung Ko
Srikala S Sridhar
Srinivas K Tantravahi
Matthew D Galsky
Daniel P Petrylak
Amitkumar N Mehta
Tomasz M Beer
Cora N Sternberg
28 September 2013
1 reference
1 reference